- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations ; volume:35 ; number:7 ; day:18 ; month:5 ; year:2018 ; pages:939-965 ; date:7.2018
Advances in therapy ; 35, Heft 7 (18.5.2018), 939-965, 7.2018
- Creator
-
Blonde, Lawrence
- Contributor
-
Dipp, Susana
Cadena, Daniel
SpringerLink (Online service)
- DOI
-
10.1007/s12325-018-0694-0
- URN
-
urn:nbn:de:101:1-2018092120434647398959
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blonde, Lawrence
- Dipp, Susana
- Cadena, Daniel
- SpringerLink (Online service)
Other Objects (12)
Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
The effects of yam gruel on lowering fasted blood glucose in T2DM rats
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Diabetes, bone and glucose-lowering agents: basic biology
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Cardiovascular outcome trials of glucose-lowering medications: an update
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort
Case-Based Optimization
Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
The effects of yam gruel on lowering fasted blood glucose in T2DM rats
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Diabetes, bone and glucose-lowering agents: basic biology
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Cardiovascular outcome trials of glucose-lowering medications: an update
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort
Case-Based Optimization
Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
The effects of yam gruel on lowering fasted blood glucose in T2DM rats
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Diabetes, bone and glucose-lowering agents: basic biology
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Cardiovascular outcome trials of glucose-lowering medications: an update
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort